Sonnet BioTherapeutics, a clinical-stage biopharmaceutical company, specializes in developing biologic drugs with enhanced mechanisms of action. Their FHAB™ platform utilizes a fully human single-chain antibody fragment (scFv) that attaches to human serum albumin (HSA) for transport to target tissues. This improves drug pharmacokinetics and enables delivery to inflammation sites, including tumors. With a focus on immune oncology, Sonnet's technology has shown significant increases in efficacy and half-life compared to other drugs in preclinical studies. The company's versatile platform has the potential to generate a large pipeline of immune oncology treatments.